A5016843734- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Treatments and Mutations
- Colorectal Cancer Treatments and Studies
- Probiotics and Fermented Foods
- Colorectal Cancer Surgical Treatments
- Cancer Treatment and Pharmacology
- Calcium Carbonate Crystallization and Inhibition
- Renal cell carcinoma treatment
- Maritime and Coastal Archaeology
- Intestinal Malrotation and Obstruction Disorders
- Breast Cancer Treatment Studies
- Adolescent and Pediatric Healthcare
- Coral and Marine Ecosystems Studies
- Inflammatory Bowel Disease
- Hormonal and reproductive studies
- Neonatal Health and Biochemistry
- Cancer, Hypoxia, and Metabolism
- Opioid Use Disorder Treatment
- Hormonal Regulation and Hypertension
- Advanced Breast Cancer Therapies
- Pain Management and Opioid Use
- Pediatric health and respiratory diseases
- Stress Responses and Cortisol
- Underwater Acoustics Research
- Colorectal Cancer Screening and Detection
Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"
2010-2021
University of Palermo
2018
Policlínica Gipuzkoa
2013
University of Calabria
2009
Azienda Ospedaliero Universitaria Ospedali Riuniti
1991
// Anna Maria Rachiglio 1 , Riziero Esposito Abate Alessandra Sacco Raffaella Pasquale Francesca Fenizia Matilde Lambiase Alessandro Morabito 2 Agnese Montanino Gaetano Rocco 3 Carmen Romano 4 Nappi Rosario Vincenzo Iaffaioli Fabiana Tatangelo 5 Gerardo Botti Fortunato Ciardiello 6 Monica R. Maiello 7 Antonella De Luca Nicola Normanno 1, Laboratory of Pharmacogenomics, CROM-Istituto Nazionale Tumori "Fondazione G. Pascale"-IRCCS, Naples, Italy Thoraco-Pulmonary, Medical Oncology, Istituto...
Two different doses of gefitinib, administered along with standard radiation therapy, were tested in locally advanced inoperable head and neck cancer the aim finding maximum tolerated dose assessing toxicity activity combination. The ‘3+3’ design was used for phase I study. Radiation therapy given according to conventional schedule. Gefitinib escalation stopped if more than one-third patients a cohort had dose-limiting toxicity. Dose-limiting observed three four treated at 500 mg, included...
Previous studies have shown the efficacy of tapentadol (TP) for chronic cancer pain. We evaluated multiple effectiveness aspects TP prolonged release on moderate-severe cancer-related pain, neuropathic pain (NeP), patient satisfaction, and quality life.An observational prospective study was conducted 80 patients. Opioid-naïve patients received a starting dose prolonged-release 50 mg twice daily, opioid-experienced were switched to TP, not exceed 500 mg/day. Treatment response at 3, 6, 30-40,...
There are very few clinical or prognostic studies on the role of SRT (Stereotactic Radiation Therapy) in continuum care metastatic colorectal cancer (mCRC) patients.Patients affected by oligo-mCRC were treated with before after front-line standard treatments. was delivered according to a risk-adapted protocol. Total body CT (Computed Tomography) scan done therapy and every three months thereafter. The radiologic responses evaluated RECIST (Response Evaluation Criteria In Solid Tumors)....
3562 Background: Bevacizumab is a humanized anti-vascular endothelial growth factor (VEGF) monoclonal antibody, approved in combination with chemotherapy the treatment of mCRC. It has been hypothesized that schedule administration might be critical and anticipating bevacizumab to improve efficacy. Present analysis updates 2016 findings Methods: mCRC pts, ≤ 75 years, ECOG PS ≤1, were randomized (1:1) receive standard (S) (5mg/kg d1 Q14) (mFOLFOX/OXXEL regimen for 12 cycles) vs experimental...
11008 Background: Early changes in tumor metabolism measured with positron-emission-tomography/computerized tomography (PET/CT) could predict the long-term efficacy of treatment better than dimensional RECIST response. Methods: We performed PET/CT before and after 1 cycle patients resectable liver metastases from colorectal cancer, within a phase II trial preoperative FOLFIRI plus bevacizumab. For each lesion, maximum SUV (SUVmax) total lesion glycolisis (TLG) were determined. both, based on...
e14130 Background: Irinotecan-based chemotherapy plus B was shown to be effective and safe in both first- second-line treatment for metastatic colorectal cancer (mCRC) pts.We designed this trial assess whether the combination of FOLFIRI + given untreated, potentially resectable mCRC pts feasible active. Methods: Phase II, single arm with 1-year progression-free rate (PFR) as primary end-point. A sample size 39 calculated detect a 70% ± 12% PFR. The q2w (irinotecan 180 mg/m2, leucovorin 200...